Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C28H41N3O3.ClH |
| Molecular Weight | 504.104 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCCN(CCC)C(=O)C(CC1=CC=C(OCCN(CC)CC)C=C1)NC(=O)C2=CC=CC=C2
InChI
InChIKey=SVCQSEFEZWMYSA-UHFFFAOYSA-N
InChI=1S/C28H41N3O3.ClH/c1-5-18-31(19-6-2)28(33)26(29-27(32)24-12-10-9-11-13-24)22-23-14-16-25(17-15-23)34-21-20-30(7-3)8-4;/h9-17,26H,5-8,18-22H2,1-4H3,(H,29,32);1H
| Molecular Formula | C28H41N3O3 |
| Molecular Weight | 467.6434 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tiropramide is an antispasmodic medication. It acts by increasing cAMP concentration in smooth muscle possibly because of inhibition of cAMP catabolism. The drug is marketed worldwide for the treatment of irritable bowel syndrome, biliary dyskinesia, acute spasmodic dysphoric syndromes, and other urological and gynecological disorders.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006939 |
19.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ALFOSPAS Approved UsePainful-spastic syndromes such as acute hepatobiliary colic, abdominal different nature, kidney or ureteral. Spasms and abdominal pain originating from gastrointestinal dyskinesia, cholelithiasis, cholecystitis, post-surgical adhesions. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
106.76 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17127027/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIROPRAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
352.81 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17127027/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIROPRAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.07 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17127027/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIROPRAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
300 mg 3 times / day multiple, oral Highest studied dose Dose: 300 mg, 3 times / day Route: oral Route: multiple Dose: 300 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
400 mg single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:30:18 GMT 2025
by
admin
on
Mon Mar 31 19:30:18 GMT 2025
|
| Record UNII |
9523013Y6R
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9523013Y6R
Created by
admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
|
PRIMARY | |||
|
57227-16-4
Created by
admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
DTXSID70972684
Created by
admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
|
PRIMARY | |||
|
236681
Created by
admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
|
PRIMARY | RxNorm | ||
|
134448
Created by
admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
|
PRIMARY | |||
|
53567-47-8
Created by
admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
|
PRIMARY | |||
|
SUB15577MIG
Created by
admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
|
PRIMARY | |||
|
m10892
Created by
admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
|
PRIMARY | Merck Index | ||
|
260-634-0
Created by
admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
|
PRIMARY | |||
|
100000091756
Created by
admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |